- Home
- AEYE vs INBX Comparison
AEYE vs INBX Comparison
Compare AEYE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- INBX
- Stock Information
- Founded
- AEYE 2005
- INBX 2010
- Country
- AEYE United States
- INBX United States
- Employees
- AEYE N/A
- INBX 161
- Industry
- AEYE Computer Software: Prepackaged Software
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- INBX Health Care
- Exchange
- AEYE Nasdaq
- INBX Nasdaq
- Market Cap
- AEYE 153.6M
- INBX 168.1M
- IPO Year
- AEYE N/A
- INBX 2020
- Fundamental
- Price
- AEYE $11.30
- INBX $11.47
- Analyst Decision
- AEYE Strong Buy
- INBX Hold
- Analyst Count
- AEYE 5
- INBX 1
- Target Price
- AEYE $26.10
- INBX N/A
- AVG Volume (30 Days)
- AEYE 141.0K
- INBX 144.3K
- Earning Date
- AEYE 04-29-2025
- INBX 05-08-2025
- Dividend Yield
- AEYE N/A
- INBX 7.40%
- EPS Growth
- AEYE N/A
- INBX N/A
- EPS
- AEYE N/A
- INBX 112.62
- Revenue
- AEYE $35,201,000.00
- INBX $200,000.00
- Revenue This Year
- AEYE $20.29
- INBX N/A
- Revenue Next Year
- AEYE $18.65
- INBX N/A
- P/E Ratio
- AEYE N/A
- INBX $0.10
- Revenue Growth
- AEYE 12.41
- INBX N/A
- 52 Week Low
- AEYE $8.91
- INBX $10.80
- 52 Week High
- AEYE $34.85
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- AEYE 46.68
- INBX 34.68
- Support Level
- AEYE $8.91
- INBX $10.81
- Resistance Level
- AEYE $11.96
- INBX $12.06
- Average True Range (ATR)
- AEYE 1.00
- INBX 1.00
- MACD
- AEYE 0.21
- INBX -0.19
- Stochastic Oscillator
- AEYE 78.36
- INBX 18.52
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's, and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.